Online Database of Chemicals from Around the World

Calicheamicin gamma 1
[CAS# 108212-75-5]

List of Suppliers
BrightGene Bio-medical Technology Co., Ltd. China Inquire  
+86 (512) 6255-1801
6255-1767
+86 13812696362
kevinwan@bright-gene.com
kevinwan0203@gmail.com
Skype Chat
QQ chat
Chemical manufacturer since 2001
chemBlink standard supplier since 2009
BOC Sciences USA Inquire  
+1 (631) 485-4226
info@bocsci.com
Chemical manufacturer
chemBlink standard supplier since 2010
Cfm Oskar Tropitzsch GmbH Germany Inquire  
+49 (9231) 9619-0
info@cfmot.de
Chemical distributor since 1985
chemBlink standard supplier since 2022
Shanghai Min-biotech Co., Ltd. China Inquire  
+86 15190045345
sales@min-biotech.com
Chemical manufacturer since 2017
chemBlink standard supplier since 2024
Zhejiang Hisun Pharmaceutical Co., Ltd. China Inquire  
+86 13818915564
hongshao.tang@hisunpharm.com
Chemical manufacturer since 1956
chemBlink standard supplier since 2024
Complete supplier list of Calicheamicin gamma 1
Identification
Classification API >> Antibiotics
Name Calicheamicin gamma 1
Synonyms LL-E 33288 gamma1-I; S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-(ethylamino)-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5Z,9R,13Z)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-3-yl]amino]oxy-4-hydroxy-2-methyloxan-3-yl] 4-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5-iodo-2,3-dimethoxy-6-methylbenzenecarbothioate
Molecular Structure CAS # 108212-75-5, Calicheamicin gamma 1, LL-E 33288 gamma1-I, S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-(ethylamino)-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5Z,9R,13Z)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-3-yl]amino]oxy-4-hydroxy-2-methyloxan-3-yl] 4-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5-iodo-2,3-dimethoxy-6-methylbenzenecarbothioate
Molecular Formula C55H74IN3O21S4
Molecular Weight 1368.35
CAS Registry Number 108212-75-5
EC Number 813-745-9
SMILES CCN[C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C#C/C=C\C#C[C@@]\4(CC(=O)C(=C3/C4=C/CSSSC)NC(=O)OC)O)C)NO[C@H]5C[C@@H]([C@@H]([C@H](O5)C)SC(=O)C6=C(C(=C(C(=C6OC)OC)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)OC)O)I)C)O)O
Properties
Solubility Practically insoluble (0.021 g/L) (25 ºC), Calc.*
Density 1.57±0.1 g/cm3 (20 ºC 760 Torr), Calc.*
Index of Refraction 1.662, Calc.*
* Calculated using Advanced Chemistry Development (ACD/Labs) Software.
Safety Data
Hazard Symbols symbol symbol   GHS07;GHS08 Danger    Details
Hazard Statements H302-H341-H361-H372    Details
Precautionary Statements P203-P260-P264-P270-P280-P301+P317-P318-P319-P330-P405-P501    Details
Hazard Classification
up    Details
HazardClassCategory CodeHazard Statement
Reproductive toxicityRepr.2H361
Germ cell mutagenicityMuta.2H341
Specific target organ toxicity - repeated exposureSTOT RE1H372
Acute toxicityAcute Tox.4H302
SDS Available
up Discovory and Applicatios
Calicheamicin gamma 1, a potent antitumor antibiotic, was discovered in the late 1970s by researchers at Wyeth-Ayerst Laboratories (now Pfizer Inc.). The discovery originated from soil samples collected in Texas, USA, containing the bacterium Micromonospora echinospora subspecies calichensis. Through a series of bioassays, calicheamicin gamma 1 was isolated and identified as the active compound responsible for its remarkable cytotoxic properties against cancer cells. Its discovery marked a significant breakthrough in the search for novel anticancer agents.

Calicheamicin gamma 1 has shown exceptional efficacy in the treatment of hematologic malignancies, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). It exerts its antitumor activity by inducing DNA cleavage through double-strand breaks, leading to apoptosis in cancer cells. As a key component of antibody-drug conjugates (ADCs), calicheamicin gamma 1 is conjugated to monoclonal antibodies targeting tumor-specific antigens, delivering cytotoxic payloads selectively to cancer cells while sparing healthy tissues. Calicheamicin gamma 1 serves as the cytotoxic payload in several FDA-approved ADCs, including gemtuzumab ozogamicin (Mylotarg) for the treatment of CD33-positive AML and inotuzumab ozogamicin (Besponsa) for relapsed or refractory B-cell precursor ALL. ADCs harness the specificity of monoclonal antibodies to target cancer cells, enabling precise delivery of calicheamicin gamma 1 to tumor sites and minimizing off-target effects, thereby enhancing therapeutic efficacy and reducing systemic toxicity. While most prominently used in hematologic malignancies, ongoing research explores the potential of calicheamicin gamma 1-based ADCs in the treatment of solid tumors. Preclinical and clinical studies are investigating novel ADCs targeting various tumor-associated antigens in solid tumors such as breast cancer, lung cancer, and ovarian cancer. These investigational therapies hold promise for expanding the therapeutic options available for patients with refractory or metastatic solid tumors. Beyond its anticancer properties, calicheamicin gamma 1 has demonstrated antibacterial activity against certain gram-positive bacteria. Research efforts continue to explore its potential applications in antibacterial therapies, particularly in combination with other antibiotics or as part of novel treatment strategies for multidrug-resistant bacterial infections.
Market Analysis Reports
List of Reports Available for Calicheamicin gamma 1
Related Products
Calcium titanate  Calcium trifluoromethanesulfonate  Calcium triple superphosphate  Calcium tungstate  Calcium valproate  Calcium zirconate  Calconcarboxylic acid  Caldiamide sodium  Calendula Extract  Calenduloside E  Calicheamicins  Calix[6]arene  Calix[4]arene  Calix[8]arene  Calmagite  Calpain  Calpain inhibitor I  Calpain inhibitor II  Calpain Inhibitor III  Calpain inhibitor VI